Acceleron Pharma (XLRN) PT Raised to $139 at Goldman Sachs
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Price: $178.75 --0%
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins raised the price target on Acceleron Pharma (NASDAQ: XLRN) to $139.00 (from $133.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Downgrades Brother Industries Ltd (6448:JP) to Neutral
- Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson Following Q2 Results
- Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
